Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions - Including a Potential Hostile Takeover of the Company - and Prevent Group from Continued Violations of Federal Securities
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July 25th
Further expansion of patent portfolio supports of the Company's extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the NetherlandsOCALA, Fla.
Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen's anti-tumor potential is demonstrated with
AIM ImmunoTech Inc. , an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19,. | April 12, 2022